Supplemental FIgure 5 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Year: 2025
Type: supplementary-materials
Abstract: Overall survival within the US cohort (n = 279) based on the presence of signaling pathway mutations including (A) NRAS, (B) KRAS, (C) PTPN11, (D) BRAF, (E) NF1, and (F) WT1. Reported p-values utilized the cox model Wald test.
Authors: Curtis A. Lachowiez, Mael Heiblig, Gaspar Aspas Requena, Emmanuelle Tavernier-Tardy, Fangyan Dai, Amenech B. Ashango, Daniel T. Peters, Jacob Fang, Andy Kaempf, Nicola Long, Christopher A. Eide, Stephen E. Kurtz, Wei Xie, Anupriya Agarwal, Aishwarya Sahasrabudhe, Christine M. McMahon, Maria L. Amaya, Gabrielle Meyers, Arpita Gandhi, Jessica Leonard, Brandon Hayes-Lattin, Richard T. Maziarz, Elie Traer, Rachel J. Cook, Ronan Swords, Theodore P. Braun, Jennifer N. Saultz, Ashley M. Eckel, Michael R. Loken, Joshua F. Zeidner, Jeffrey W. Tyner, Daniel A. Pollyea
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4413960852